Miriam Kidron - 22 Jan 2026 Form 4 Insider Report for ORAMED PHARMACEUTICALS INC. (ORMP)

Role
Chief Scientific Officer, Director
Signature
/s/ Miriam Kidron
Issuer symbol
ORMP
Transactions as of
22 Jan 2026
Net transactions value
$0
Form type
4
Filing time
29 Jan 2026, 16:05:33 UTC
Previous filing
21 Jan 2026
SEC
View on sec.gov

Reporting Owners (1)

Name Relationship Address Signature Signature date CIK
Kidron Miriam Chief Scientific Officer, Director 1185 AVENUE OF THE AMERICAS, THIRD FLOOR, NEW YORK /s/ Miriam Kidron 29 Jan 2026 0001409232

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ORMP Common Stock Options Exercise $0 +19,000 +1.3% $0.000000 1,448,664 22 Jan 2026 Direct F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ORMP Performance Stock Units Options Exercise $0 -19,000 -100% $0.000000 0 22 Jan 2026 Common Stock 19,000 Direct F1, F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Represents the vesting of performance stock units ("PSUs") granted to the Reporting Person on December 31, 2025, which vested on January 22, 2026, upon the Issuer's common stock, par value $0.012 per share ("Common Stock"), achieving a specified price per share. The shares of Common Stock were received for no consideration upon such vesting.
F2 Each PSU represented a contingent right to receive one share of the Issuer's Common Stock upon achievement of the applicable performance criteria.